Marco M.
- Country
- Italy
- Department
- S.C. Medicina Nucleare
Research Overview
- Evaluation of Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Advanced Unresectable or Metastatic NSCLC, BC, PDAC, and CRC.
- Phase Ib/II Study of Lutetium (177Lu) Oxodotreotide in Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
- Phase III Study on the Efficacy and Safety of 177Lu-Edotreotide PRRT Versus Everolimus in Inoperable, Progressive SSTR+ GEP-NET Patients
Data & Insights
Has run more than one trial at 23 of 59 partner sites.
Specializations
Thyroid Cancer Research
Specializes in personalized therapy approaches for metastatic differentiated thyroid cancer, with particular focus on dosimetry-based radioiodine treatment.
- Advanced imaging techniques using 124I PET
- Molecular characterization of thyroid tumors
- Treatment of skeletal and soft tissue metastases
Investigates therapeutic responses through genetic and molecular profiling.
Advanced Solid Tumors
Focuses on developing innovative treatments for multiple advanced cancer types using targeted radiopharmaceutical approaches.
- Non-small cell lung cancer
- Metastatic breast cancer
- Pancreatic ductal adenocarcinoma
- Advanced colorectal cancer
Evaluates novel radioligand therapies for metastatic disease.
Neuroendocrine Tumor Treatment
Specializes in peptide receptor radionuclide therapy (PRRT) for gastroenteropancreatic neuroendocrine tumors.
- First-line treatment strategies
- High-grade GEP-NET management
- Combination therapy approaches
Studies comparative effectiveness of PRRT versus conventional treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.